JNJ · News · 20261102N

Oncology Pipeline Progress

JOHNSON & JOHNSON · 2026-11-02 · Importance 34 · Surprise 42

At the 2026 ESMO Congress, Johnson & Johnson presented positive oncology data, including OrigAMI 4 results for subcutaneous amivantamab in head and neck cancer. The report says the treatment showed high overall response rates and may support the company’s next wave of cancer assets. The data relate to efforts to offset competition to STELARA and other pricing and patent challenges.

Key facts

• Johnson & Johnson announced positive oncology data from the 2026 ESMO Congress, including OrigAMI 4 data for subcutaneous amivantamab in head and neck cancer showing high overall response rates. source
• At ESMO 2026, Johnson & Johnson presented over 25 abstracts, including data on earlier intervention in high-risk prostate cancer and a new treatment combination for head and neck cancer. source